Massive Bio CEO Touts AI Strategy at NYSE
Selin Kurnaz, CEO of Massive Bio, discussed the company's use of AI in healthcare and clinical trials in a segment hosted by the NYSE. The discussion focused on how AI can improve patient access and enable scaling of operations. This serves as an example of a CEO using capital market platforms to communicate a company's technology and AI narrative directly to the investment community.
- Co-founder and CEO Selin Kurnaz has a background in both engineering and finance, holding five engineering degrees including a Ph.D. from the University of Michigan and having helped establish EY's Private Equity Value Creation team for healthcare investments. - The company's core AI platform, SYNERGY-AI, uses natural language processing to analyze unstructured medical records and match patients to a database of over 19,000 oncology trials. This is augmented by physician-facing tools like "Dr. Arturo AI" and patient-facing tools like "Ask Fiona AI". - Massive Bio is a Series B company that has raised a total of $15.6 million over four funding rounds, with its most recent being a $9 million round in June 2022 led by Revo Capital. - The company's business model serves pharmaceutical firms and contract research organizations (CROs) by accelerating patient recruitment, a major bottleneck in drug development. - Kurnaz was motivated to start the company in 2014 after a family member's experience with cancer, with the stated mission of using technology to overcome geographical and financial barriers to clinical trial access. - In late 2025, the company announced its next-generation platform, Reticulum Nexus, an AI-driven multi-agent system designed to orchestrate the entire patient journey from initial contact to enrollment. - The platform has onboarded more than 160,000 cancer patients and the company operates in 12 countries, partnering with pharmaceutical companies to enable population-based recruitment rather than traditional site-specific methods.
